Clinical trial
Effect Of Celecoxib On Hip Osteoarthritis (OA) Progression
NCT00163241 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Terminated
Key facts
| NCT number | NCT00163241 |
|---|---|
| Title | Effect Of Celecoxib On Hip Osteoarthritis (OA) Progression |
| Official title | A Double-Blind, Placebo-Controlled, Randomized 24-Month Study, Assessing The Effect Of Celecoxib (Celebrex) Long Term Treatment On Hip Osteoarthritis (OA) Progression OSCARE |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoarthritis |
| Intervention type | Drug |
| Interventions | celecoxib |
| Enrollment | 666 |
| Start date | Jun 1, 2004 |
| Completion | Jan 1, 2006 |
| First posted | Sep 13, 2005 |
| Last update posted | Mar 3, 2021 |
| Countries | Canada, France |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: